Office for Technology Commercialization

Mammalian Cell Culture System for Anaplasmosis Vaccine Development

Technology #z02209

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Anaplasmosis AntigenAnaplasma phagocytophiliumAnaplasma
Ulrike Munderloh, PhD
Associate Professor, Department of Entomology, College of Food, Agricultural and Natural Resource Sciences
External Link (
Managed By
Raj Udupa
Technology Licensing Officer 612-624-3966
Patent Protection
US Patent 7,361,504

Anaplasma phagocytophilium

Anaplasmosis is a disease caused by Anaplasma phagocytophilium. This intracellular bacterium is transmitted via infected tick bites, and infects humans and animals in North America, Europe, Australia, and Africa. A method of propagating Anaplasma species stably in mammalian cells would assist both industry and academia research and development.

Culturing Anaplasma for Antigen Use

A way to propagate Anaplasma species in mammalian cells has been developed at the University of Minnesota. An Anaplasma species stably infects a mammalian endothelial cell, which is propagated then isolated. This culturing system allows for genetic analysis and provides a source of Anaplasma for use as an antigen for potential anaplasmosis diagnostics or treatments.

MN-IP Try and Buy
This research method is immediately available for a nonexclusive license. Contact Raj Udupa for specific details.


  • Provides cells that are stably infected with Anaplasma species
  • Allows for propagation of Anaplasma species in mammalian cells for at least 8 weeks
  • Isolation of Anaplasma species for research use

Fulfillment Details

Licensee will receive rights to practice the intellectual property (Patent) for the purposes of developing and manufacturing a commercial product.

Phase of Development

In Vitro Assessment